The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Lentivirus-mediated antagomir expression for specific inhibition of miRNA function
Open accessAbstract
Micro RNAs (miRNA) regulate gene expression by hybridization and recruitment of multi-protein complexes to complementary mRNA target sequences. miRNA function can transiently be antagonized by antagomirs-chemically modified oligonucleotides complementary to individual miRNAs. Here, we describe the induction of stable loss-of-function phenotypes for specific miRNAs by lentivirus-mediated antagomir expression. Lentivirally expressed antagomirs are transcribed from a H1-promoter located within the lentiviral 3'LTR and were directed against miRNAs encoded on the polycistronic miR17-92 transcript. Functional silencing of miR-18a, miR-19b and miR-20a by the corresponding antagomirs specifically relieves miRNA-mediated reporter gene repression. Inhibition of miRNA function correlates to reduction of 'miRNA' amplification by miRNA-specific quantitative RT-PCR. Furthermore, protein expression of E2F-1, a known miR-20 target, is enhanced by lentivirally expressed anti-miR-20 antagomirs in a dose-dependent manner, whereas over-expression of miR-20a reduces E2F-1 levels. Finally, combined over-expression of specific miRNAs and antagomirs reveals individual and complementary functions of miR-18a and miR-20a and demonstrates specific miRNA impact on cell proliferation in a cell culture model.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
Cited by
Lu, T. X., & Rothenberg, M. E. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.08.034 · Cited by 2,425
MicroRNA sponges: Progress and possibilities
Ebert, M. S., & Sharp, P. A. (2010) · RNA · doi:10.1261/rna.2414110 · Cited by 762
“…(Franco-Zorrilla et al. 2007), decoys (Carè et al. 2007), miRNA target (miRT) sequences (Gentner et al. 2009), miRNA erasers (Sayed et al. 2008), and lentivirus-mediated antagomirs (Scherr et al. 2007; for currently available miRNA sponge constructs and their intended applications, see Table 1).”
InfluentialTissue mechanics modulate microRNA-dependent PTEN expression to regulate malignant progression
Mouw, J. K., Yui, Y., Damiano, L., Bainer, R. O., Lakins, J. N., Acerbi, I., Ou, G., Wijekoon, A. C., Levental, K. R., Gilbert, P. M., et al. (2014) · Nature Medicine · doi:10.1038/nm.3497 · Cited by 396
Miroshnikova, Y. A., Mouw, J. K., Barnes, J. M., Pickup, M. W., Lakins, J. N., Kim, Y., Lobo, K., Persson, A. I., Reis, G. F., McKnight, T. R., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3429 · Cited by 383
MicroRNAs: novel regulators in cardiac development and disease
Thum, T., Catalucci, D., & Bauersachs, J. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvn137 · Cited by 377
He, X.-X., Chang, Y., Meng, F.-Y., Wang, M.-Y., Xie, Q.-H., Tang, F., Li, P.-Y., Song, Y.-H., & Lin, J.-S. (2012) · Oncogene · doi:10.1038/onc.2011.500 · Cited by 339
Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications
Brown, B. D., & Naldini, L. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2628 · Cited by 336
Haraguchi, T., Ozaki, Y., & Iba, H. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp040 · Cited by 305
Stable knockdown of microRNA in vivo by lentiviral vectors
Gentner, B., Schira, G., Giustacchini, A., Amendola, M., Brown, B. D., Ponzoni, M., & Naldini, L. (2009) · Nature Methods · doi:10.1038/nmeth.1277 · Cited by 304
miRNAs in Cancer (Review of Literature)
Smolarz, B., Durczyński, A., Romanowicz, H., Szyłło, K., & Hogendorf, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052805 · Cited by 296
microRNAs: Master Regulators as Potential Therapeutics in Cancer
Garofalo, M., & Croce, C. M. (2011) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100517 · Cited by 291
A microRNA expression signature of osteoclastogenesis
Sugatani, T., Vacher, J., & Hruska, K. A. (2011) · Blood · doi:10.1182/blood-2010-10-311415 · Cited by 275
Micro RNA‐24 regulates cardiac fibrosis after myocardial infarction
Wang, J., Huang, W., Xu, R., Nie, Y., Cao, X., Meng, J., Xu, X., Hu, S., & Zheng, Z. (2012) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2012.01523.x · Cited by 266
MicroRNAs in neurodegenerative diseases and their therapeutic potential
Junn, E., & Mouradian, M. M. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.10.002 · Cited by 186
Next-generation AAV vectors—Do not judge a virus (only) by its cover
Domenger, C., & Grimm, D. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz148 · Cited by 147
MicroRNA as an Important Target for Anticancer Drug Development
Fu, Z., Wang, L., Li, S., Chen, F., Au-Yeung, K. K.-W., & Shi, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.736323 · Cited by 133
Chan, X. H. D., Nama, S., Gopal, F., Rizk, P., Ramasamy, S., Sundaram, G., Ow, G. S., Vladimirovna, I. A., Tanavde, V., Haybaeck, J., et al. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.07.012 · Cited by 84
Papapetrou, E. P., Korkola, J. E., & Sadelain, M. (2010) · Stem Cells · doi:10.1002/stem.257 · Cited by 73
Managing MicroRNAs with Vector-Encoded Decoy-Type Inhibitors
Bak, R. O., Hollensen, A. K., & Mikkelsen, J. G. (2013) · Molecular Therapy · doi:10.1038/mt.2013.113 · Cited by 49
Metadata
- Authors
- Scherr, M., Venturini, L., Battmer, K., Schaller-Schoenitz, M., Schaefer, D., Dallmann, I., Ganser, A., & Eder, M.
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-11-26
- Volume
- 35
- Issue
- 22
- Pages
- e149-e149
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- OpenAlex
- W2168414025
- Cited by
- 190
- References
- 1
- FWCI
- 4.93
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.